Pharmaniaga Turns Quarter Around Recording RM101 Million In Profits
Pharmaniaga Turns Quarter Around Recording RM101 Million In Profits
However, this growth was also partially offset by a decline in revenue in the non-concession segment, which was impacted by the completion of the supply of a blood product.For the third quarter ended 30 September 2024, Pharmaniaga Berhad recorded RM1,029.8 million in revenue, reflecting a 16.3% increase from RM885.5 million in the corresponding quarter of the previous financial year. This growth was primarily driven by the increased demand in the concession segment, attributed to the addition of new products to the Approved Product Price List and price adjustments.
在截至2024年9月30日的第三季度中，Pharmaniaga Berhad的收入爲102980萬令吉，較上一財年同期的88550萬令吉增長了16.3％。這種增長主要是由特許權細分市場需求的增加所推動的，這歸因於批准的產品價目表中增加了新產品和進行了價格調整。
Profit after tax improved significantly from a loss in Q3FY23 to RM101 million in the current quarter.
稅後利潤從 Q3FY23 的虧損大幅提高到本季度的10100萬令吉。
The group said the higher revenue was also contributed by increased customer demand in the Indonesia segment, fuelled by a surge in orders from existing principals and additional sales generated from the opening of two new branches in February 2024.
該集團表示，收入的增加還得益於印度尼西亞板塊客戶需求的增加，這得益於現有負責人的訂單激增以及2024年2月開設兩家新分支機構所產生的額外銷售額。
However, this growth was also partially offset by a decline in revenue in the non-concession segment, which was impacted by the completion of the supply of a blood product.
For the period under review, the lower net cash generated from operations was mainly due to the payment of the overdue suppliers. With the higher revenue in the current quarter and the absence of substantial one-off impairments and provisions recorded in the previous corresponding quarter—such as the provision for stock obsolescence of expiring pandemic-related consumables (e.g., personal protective equipment and needles), the write-off of new product development costs due to the non-commercial viability of certain products, and the cessation of non-core businesses, which also led to a write-down of machinery and equipment—the Group's earnings before interest, taxation, depreciation and amortisation (EBITDA) rebounded
significantly to RM166.2 million, compared to a loss before interest, taxation, depreciation and amortisation (LBITDA) of RM30.7 million in the corresponding quarter of the previous year.
但是，非特許權板塊收入的下降也部分抵消了這一增長，這受到血液製品供應完成的影響。
在本報告所述期間，業務產生的淨現金減少的主要原因是向逾期供應商付款。由於本季度收入增加，且上一個相應季度沒有大量的一次性減值和準備金，例如爲即將到期的疫情相關消耗品（例如個人防護設備和針頭）的庫存報廢準備金，註銷某些產品的非商業可行性而產生的新產品開發成本，以及非核心業務的停止，這也導致了機械和設備的減記——集團扣除利息、稅項、折舊前的收益攤銷（息稅折舊攤銷前利潤）反彈
與去年同期扣除利息、稅項、折舊和攤銷（LBITDA）前的虧損（LBITDA）相比，大幅達到16620萬令吉。
Higher payables as of 30 September 2024 were primarily due to increased purchases resulting from the addition of new products to the Approved Product Price List in the new concession period, as well as price revisions under the new concession cycle due to increased supplier costs. Additionally, higher revenue was also contributed by increased customer demand in the Indonesia segment, fueled by a surge in orders from existing principals and additional sales generated from the opening of two new branches in February 2024. However, this growth was partially offset by a decline in revenue in the non-concession segment, which was impacted by the completion of the supply of a blood product.
截至2024年9月30日，應付賬款增加的主要原因是，在新的特許期內將新產品添加到批准的產品價目表中，導致購買量增加，以及供應商成本增加導致新特許週期內的價格修訂。此外，在現有負責人的訂單激增以及2024年2月開設兩家新分支機構所產生的額外銷售額的推動下，印度尼西亞細分市場客戶需求的增加也推動了收入的增加。但是，非特許權板塊收入的下降部分抵消了這一增長，這受到血液製品供應完成的影響。
Correspondingly, the Group's profit before zakat and taxation (PBT) showed a significant improvement to RM138.5 million, compared to a loss before zakat and taxation (LBT) of RM56.3 million in the corresponding quarter of the previous year.
相應地，集團的稅前利潤（PBT）顯著改善，達到13850萬令吉，而去年同期的稅前虧損（LBT）爲5630萬令吉。
譯文內容由第三人軟體翻譯。
